Page 11234..10..»

Archive for the ‘Dental Stem Cells’ Category

Mouth Sores from Chemo: Symptoms, Causes, and Treatments – Healthline

Friday, February 19th, 2021

While youre receiving treatment for cancer, some of the drugs you take can cause painful sores to develop inside your mouth. You can also get them if youve had a bone marrow (stem cell) transplant as part of your cancer care.

Although they often heal on their own, these mouth sores can make it uncomfortable to eat and talk. Well discuss what you can do to relieve the pain and prevent them from getting worse.

Mouth sores can be a common side effect of cancer treatment. The condition, known as stomatitis or mucositis, is an inflammation of the tissues inside your mouth.

Whitish, ulcer-like sores can form on your cheeks, gums, lips, tongue, or on the roof or floor of your mouth. Even if you dont develop mouth ulcers, you may have patches that feel inflamed and painful, as if theyve been burned.

Anyone who is receiving chemotherapy, radiation therapy, or a bone marrow (stem cell) transplant can develop mouth sores as a side effect of these treatments.

If you have dry mouth or gum disease, or if your teeth and gums are not well taken care of, you may be at a higher risk of getting mouth sores during your treatment. Women and people who smoke or drink alcohol are also at a higher risk, according to the Oral Cancer Foundation.

If youre receiving chemotherapy, the sores could begin forming anywhere from 5 days to 2 weeks after your treatment. Depending on the specific cause, the sores could go away on their own in a few weeks, or they could last longer.

Its important to find ways to manage your pain and to watch for signs of an infection. Cancer-related mouth sores can lead to weight loss, dehydration, and other serious complications.

Cancer cells can grow very quickly. The aim of cancer treatment is to stop or slow down that growth. The cells in the mucous membranes lining your mouth are also fast-growing cells, so cancer treatments affect them, too.

Cancer treatments also keep the cells in your mouth from being able to repair themselves efficiently when theyre damaged.

Radiation therapy can also damage the glands in your mouth that make saliva. A dry mouth is more susceptible to infections that cause mouth sores.

Chemotherapy and radiation can both change the microbiome in your mouth, upsetting the balance between good and bad bacteria. The growth of harmful bacteria in your mouth can also lead to mouth sores.

Sometimes cancer treatments suppress your immune system, which may make it more likely that youll get a bacterial, viral, or fungal infection that causes mouth sores. An older infection (such as the herpes simplex virus) can also suddenly flare up again.

If youve had a bone marrow (stem cell) transplant, sores may be a sign that youve developed a condition known as graft-versus-host disease (GVHD).

When this happens, the cells in your body are attacking the transplanted cells as though they were an unhealthy invader. According to research published in Journal of Clinical and Experimental Dentistry, short-term (acute) GVHD occurs in 50 to 70 percent of stem cell transplant cases and longer-term (chronic) GVHD is seen in 30 to 50 percent of cases.

The form of GVHD that causes mouth sores is usually mild, and doctors often treat it with corticosteroid medications.

Its important to talk with your doctor if you develop mouth sores after a stem cell transplant, as some kinds of GVHD can turn serious if left untreated.

There is a good chance that youll experience mouth sores at some point during your cancer treatment. Researchers estimate that 20 to 40 percent of those who have chemotherapy and 80 percent of those who have high-dose chemotherapy will develop mucositis afterward.

Still, there are steps you and your cancer care team can take to lower your risk, reduce the severity of the sores, and promote faster healing.

About a month before your cancer treatment begins, schedule an appointment with your dentist to make sure your teeth and gums are healthy. If you have cavities, broken teeth, or gum disease, its important to come up with a dental treatment plan to take care of these conditions so they dont lead to infections later, when your immune system may be vulnerable.

If you wear braces or dentures, ask your dentist to check the fit and remove any part of the device you dont need during your treatment.

Its very important to maintain good oral hygiene practices throughout your treatment to lower your risk of infection. Brush and floss gently but regularly, avoiding any painful areas. You can also ask your dentist whether a mouth rinse with fluoride is advisable in your case.

For certain kinds of chemotherapy (bolus 5fluorouracil chemotherapy and some high-dose therapies), your healthcare team may give you ice chips to chew for 30 minutes before your treatment. This type of cold therapy can lower your risk of getting mouth sores later.

During treatment of some blood cancers, doctors may give you injections of palifermin, also known as human keratinocyte growth factor-1 (KGF-1), to prevent mouth sores.

If youre scheduled to receive high-dose chemotherapy or radiotherapy, your cancer care team may prepare your mouth using low-level laser therapy beforehand to keep you from getting mouth sores.

For people who have radiation therapy for head and neck cancers, doctors may prescribe this medicated mouthwash to minimize mouth sores.

The length of time your mouth sores may last depends on the specific cancer treatment youve had. Here are some estimates broken down by treatment:

You may notice symptoms anywhere between a few days and a few weeks after your cancer treatment. Heres what you may see and feel as mucositis develops:

You may notice that the sores become slightly crusty as they heal. Its important to keep track of your symptoms and let your oncologist know if the sores arent healing on their own.

Contact your doctor right away if you:

Untreated mouth sores can lead to malnutrition, dehydration, and life-threatening infections.

There are a few different ways that you can help mouth sores heal and avoid prolonger pain or an infection.

While the sores are healing, its very important to keep the inside of your mouth clean to prevent an infection from developing.

The National Cancer Institute recommends that you gently clean your teeth every 4 hours and just before you go to sleep at night. Here are a few tips to consider:

If the pain from mouth sores is interfering with your ability to eat and drink, your doctor may treat the condition with a opioid mouthwash or one containing doxepin or lidocaine.

To ease discomfort and keep your mouth from feeling dry, you may want to try rinsing with a mild saltwater or baking soda solution. Heres how to make each of them:

Your cancer care team may recommend that you use a lubricating liquid (artificial saliva) to moisten the inside of your mouth if dryness is a problem. These liquids are usually gel-like. They coat your mouth with a thin film to help ease discomfort and promote healing.

Some people have found it useful to rinse with a blend of medications called the magic mouthwash. Formulas for this mouthwash vary, but most of them include a combination of medications to treat different symptoms, including:

Magic or miracle mouthwash solutions usually have to be prescribed by a doctor and prepared by a pharmacist, although some people mix up an over-the-counter version at home.

There isnt enough research to say for sure whether magic mouthwash works. If you think youd like to try it, talk with your oncologist or a healthcare professional about whether its a good idea for you.

Here are a few more things you can try at home that may help ease pain from mouth sores:

Mouth sores are one of the most common side effects of cancer treatment. Shortly after chemotherapy, radiation, or transplant treatments, painful, ulcer-like sores can form on the inside of your mouth.

These sores may go away on their own. If they dont, its important to seek medical treatment for them because they can lead to very serious complications.

Before you start cancer treatments, visit a dentist to make sure your teeth and gums are healthy. Keeping up good dental hygiene practices during and after cancer treatment will help limit mouth sores.

If the sores are keeping you from eating and drinking, talk with your oncologist about medications could relieve the pain and speed up the healing process, so you can enjoy a better quality of life during treatment.

Its really important to keep track of any sores in your mouth so you can reach out to your healthcare team if they dont improve. Sores that deepen or worsen can lead to serious even life-threatening complications.

See the article here:
Mouth Sores from Chemo: Symptoms, Causes, and Treatments - Healthline

Read More...

Tooth Regeneration Market to Exhibit Steadfast Expansion by 2027 | Unilever, Ocata Therapeutics, Integra LifeSciences, CryoLife, BioMimetic…

Sunday, February 14th, 2021

The report provides study at global and regional level to provide comprehensive value market analysis for the years (2017 & 2018 Historic Years, 2019 Base Year and 2020-2027 Forecast Period). The Tooth Regeneration Market research report is a wide-ranging study of current trends, market growth drivers, and restraints. Each market segment is broadly analyzed at a powdered level by region (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America) to provide thorough information on the global and regional level.

Tooth regeneration is a regenerative surgical technique based on stem cells that is used in the fields of tissue engineering and stem cell biology. By developing it from autologous stem cells, the tooth regeneration procedure restores the weakened or missing tooth. With the aid of reabsorbable biopolymer, somatic cells are harvested and reprogrammed to stimulate pluripotent stem cells and dental lamina.

Some of the key players in this market include

Download Sample PDF Brochure of this research study at https://www.theinsightpartners.com/sample/TIPRE00018967/

The Tooth Regeneration Market is segmented on the basis of services and application. Based on services , the market is segmented as Medical Writing and Publishing, Medical Monitoring, Medical Science Liaisons (MSLs), Medical Information, Others. Based on application, the market is segmented as pharmaceutical, biopharmaceutical, medical devices.

The segmentation in this research study has been finalized post in-depth secondary research and extensive primary research. In addition, the market is also segmented on the basis of technology offered by the leading participants in the industry in order to understand widely used market specific terminologies. Thus, we have incorporated the segments of the research and have finalized the market segmentation.

The Insight Partners Tooth Regeneration Market Research Report Scenario includes:

Order a copy of this research study at https://www.theinsightpartners.com/buy/TIPRE00018967/

The report also covers a detailed chapter of the analysis on COVID-19 impact on this market at global and regional level in our final reports.

This research provides detailed information regarding the major factors influencing the growth of the Tooth Regeneration Market in Global and Regional Level (drivers, restraints, opportunities, and challenges), forecast of the market size, in terms of value, market share by region and segment; regional market positions; segment and country opportunities for growth; New product developments, strengths and weaknesses, brand portfolio; Marketing and distribution strategies; challenges and threats from current competition and prospects; Key company profiles, SWOT, product portfolio and growth strategies.

ABOUT US:

The Insight Partners is a one stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialist in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Our research model is very simple. We believe in client servicing and delivering best quality to our customers. Through our research content, we are making sure that our customers get value of their money along with better quality data and analysis.

Our research content is majorly focused towards market trends in terms of market sizing, competitive landscaping, company analysis, regional or country analysis etc. We provide detailed break-up of segmentation in terms of geography, technology, product and services etc.; which helps our clients to get a deeper analysis on various research topics.

Contact US:

If you have any queries about this report or would like further information, please contact us:

North America: +1 646 491 9876

Asia-Pacific: +91 20 6727 8686

Email: [emailprotected]

https://neighborwebsj.com/

Go here to see the original:
Tooth Regeneration Market to Exhibit Steadfast Expansion by 2027 | Unilever, Ocata Therapeutics, Integra LifeSciences, CryoLife, BioMimetic...

Read More...

Using 3D Printing to Develop Bone-Like Structures that Contain Living Cells – AZoM

Sunday, February 14th, 2021

AZoM speaks withDr. Iman Roohani from UNSW.Dr.Roohani is part of a team of researchersthat developed a technique referred to as Ceramic Omnidirectional Bioprinting in Cell-Suspensions (COBICS). This techniquecould allow surgeons to print structures that can be submerged in water and hardened within just minutes, resembling natural bone.Even more revolutionary, the structures contain living cells that continue to grow after they are implanted.

We have developed a technique (COBICS) that enables printing constructs with the same chemistry to native bone mineral at room temperature with living cells. These structures are the most accurate mimics of the bone tissue. COBICS can print complex and biologically relevant architecture constructs without the need for sacricial support materials, on-spot and laborious post-processing steps.

COBICS has two main components. A chemically cross-linked microhydrogel bath with optimized yield-stress properties that support the printing of the ceramic ink, the second component, in the presence of live cells. The ink is a calcium phosphate paste with a specific formulation that allows the material to be used directly in the aqueous environment, without the need for any post-processing steps, such as high-temperature treatments, that are required for other types of existing ceramic materials.

Once ink comes in contact with the microgel, nanocrystalization kicks off at the interface between ink and hydrogel, which further locks the filament in place. Since this ink can harden quickly without imposing adverse effects on living cells, COBICS enables printing within a suspension of living cells to achieve complex bone shapes, where the cells integrate to form natural bone tissue.

Traditional bone grafts, particularly synthetic ones, are mostly fabricated from ceramic materials at high temperatures, which disallows integration with cells and growth factors. Moreover, due to high temperature processing, the microstructure of such grafts does not resemble the native bone.

COBICS paves the way to fabricate autologous graft like structures in the laboratory, which significantly reduces the risks and drawbacks involved in harvesting these grafts from the patient in the clinical setting by using only cells from the patient or other sources of regenerative cells. This also could enable patient-specific real-time bone reconstruction where the bioprinter could directly print new bone into the resected space.

You could even isolate the patient's stem cells before surgery for inclusion with the ink to improve the integration of the new bone into the surgery site or in dental reconstruction. In another example, drugs could be integrated with the ink for sustained release over time to increase natural bone formation, combat bacteria, or influence the immune system (e.g., enhance wound healing).

The ink has an essential role in printing the constructs by the COBICS technique. The optimization process of formulating the ink took around 2 years since we had to ensure that ink has several properties that were mutually exclusive. Those properties included biocompatibility, being printable, proper setting time, adequate strength and firmness after printing, and printing in contact with the microgel bath.

We have an ongoing animal study at the moment, that will hopefully confirm our hypothesis that there should be no harmful components in our material.Thus far, all of our tests with human cells in the laboratory have confirmed high biocompatibility. We plan to scale up our production of bone-like grafts and test the regenerative properties of the printed grafts in large animal models before proceeding with humantrials and regulatory approval.If everything goes well and we findexternal funding support,we are optimistic the technique may be ready for the clinic within 5 years.

Readers can check out the full article at https://doi.org/10.1002/adfm.202008216.

From 2010 to 2014, Dr. Roohani studied and received his Ph.D. degree at the School of Aerospace, Mechanical and Mechatronic Engineering at the University of Sydney (USYD) in Sydney, Australia. From 2016 to 2020, he worked in the field of biomaterials and tissue engineering as the National Health and Medical Research Council (NHMRC) early career fellow, first in the biomedical engineering department at the University of Sydney, and then at the School of Chemistry in the University of New South Wales (UNSW).

Dr. Roohani is interested in the use of biomaterials as the bone substitute, drug delivery and instructive source for cells. More specifically, his interests comprise synthesis and development of a range of bioceramics, including calcium phosphates, understanding of the interaction between living cells and synthetic substrates, and translation of the application of these materials and concepts to clinical applications.

Dr. Roohani is the inventor of several patented products, including the COBICs techniques. He is the author of more than 60 peer-reviewed publications (h index of 23), book chapters, and 3 patent applications.

ResearchGate: https://www.researchgate.net/profile/Iman_Roohani

Twitter: @ImanRoohani

Email:[emailprotected]

Google Scholar:https://scholar.google.com.au/citations?user=NyzEeygAAAAJ&hl=en

Disclaimer: The views expressed here are those of the interviewee and do not necessarily represent the views of AZoM.com Limited (T/A) AZoNetwork, the owner and operator of this website. This disclaimer forms part of the Terms and Conditions of use of this website.

See the original post:
Using 3D Printing to Develop Bone-Like Structures that Contain Living Cells - AZoM

Read More...

Fear of Covid keeps patients away from dental clinics resulting in an increased need of treatment. – ETHealthworld.com

Tuesday, February 9th, 2021

The new health guidelines have allowed private dental clinics to start functioningNew Delhi : Observably, the Covid-19 pandemic hit a pause button on many of our routine activities, including regular visits to the dentist. When the pandemic peaked, health authorities put restrictions in place for dental care, and dental clinics saw only emergency cases and advised patients to wait when it came to non-essential or non-urgent procedures including regular check-ups, cleaning, fillings, etc., which resulted in a substantial drop in the preventive dental care visits of oral patients across India.

Lt Gen. Dr Vimal Arora, Chief Clinical Officer, Clove Dental said, Oral Health data in India says that 8 out of 10 Indians suffer from some or the other kind of dental diseases which clearly reflects that Oral & Dental Health has always been deprioritized even in pre-Coovid times. However, with this pandemic people have further delayed their dental visits for past 10 months, the result of which is that the oral health conditions which could have been handled with simple cavity filling, now need RCT & Crowning and even extraction in some cases leading to loss of tooth. Ministry of Health and Family Welfare estimates that currently (2019), about 60% of Indias adult population and 70% of its school-going children are affected by dental caries (cavities) or tooth decay. And, periodontal disease infections of the tissue around the teeth has ended up affecting at least 85% of the population. The country is also considered the world capital for oral cancer. Of the total body cancers, Oral cancers accounts for over 30% of all body cancers.

Drop in Dental Care

Dr Anirudh Singh, General Manager, Clove Dental, South West India said, Traditionally, check-ups are recommended every six months. But people often ignore this, which leads to the severity of the dental problems demanding expensive treatments and care. According to the draft National Oral Health Policy, the proportion of untreated caries of permanent teeth and severe periodontitis is the maximum compared to other oral disorders. Yet, only 12.4% of adults have ever had their mouth examined by a dentist. Routine check-ups are the part of preventive treatments. However, due to COVID, preventive treatments have gone down by 63.7%, as the patient visits have declined. As COVID has prompted the delay in treatments, we see the need for more restorative treatments now. Therefore, prioritising dental care is as important as any other healthcare problems.

A fundamentally different approach is required to effectively tackle the global burden of oral diseases. The public health problems associated with oral diseases are a serious burden in every nation around the globe. What is lacking is the awareness to the disease and the information as to what all poor oral health can create in the body. Excellent dental health is the gateway for the overall body health; is the true slogan.

The rest is here:
Fear of Covid keeps patients away from dental clinics resulting in an increased need of treatment. - ETHealthworld.com

Read More...

3D medical printing making strides, and helping patients do the same – MedCity News

Tuesday, February 9th, 2021

3d printing human body. 3d printed implants on white background.

Back in the 1970s, there was a television show called The Six-Million-Dollar Man about a fictional astronaut severely injured in a test crash, and then having several body parts replaced by robotics. The shows opening narration promised that he would be better than he was before. Better. Faster. Stronger.

Life is now imitating art, and then some. 3D printers are currently being used to construct not only customized prosthetics for patients in need, but a wide variety of other medical items foremost among them tissues and organoids, as well as surgical models and tools. It is estimated that 13 percent of 3D printing revenue comes courtesy of the medical field, and that some $3.19 billion will be spent on technology in that sector by 2025. Thats over $2 billion more than in 2018 ($1.13 billion), a compound annual growth rate (CAGR) of 15.89 percent.

There are many reasons for this uptick, not the least of which are that these items can be produced quickly and inexpensively. But there is none bigger than the ever-increasing demand for prosthetics. Some 30 million people around the world, including 1.9 million in the U.S., are in need of such devices, and as of 2018 only 20 percent of them had been provided for.

Factor in other devices and an aging population with a consequent increase in demand for personalized treatment as noted by Tim Deng, Principal Medical Devices Analyst at GlobalData, in a report on the website Express Healthcare and the overwhelming need becomes that much clearer.

So too are the benefits of meeting that need. Better, faster, stronger? Well, that part might be a bit of a stretch, at least for now. But certainly it appears that 3D printers are making it possible for patients to be as good, as fast and as strong as they were before illness or injury left them a shell of their former selves.

Serendipity helped galvanize the 3D prosthetics industry. In 2011 an artist named Ivan Owen developed a puppet hand for a steampunk event i.e., an event where modern technology melds with elements of Victorian-era history and fashion. He circulated a video of his creation, which was seen by Richard Van As, a South African carpenter who, having just lost four fingers in an accident, was looking for a prosthetic hand that would enable him to return to work. The two of them collaborated to construct just such a device, then used a 3D printer to develop another for a five-year-old boy who was born without fingers.

Owen, instead of patenting his invention, elected to open-source it. That led in 2013 to the formation of the nonprofit organization e-NABLE, an online community enabling people to collaborate on the design of 3D prosthetic limbs. Another nonprofit, Limbitless Solutions, came along a year later, with the mission of providing 3D-printed arms for children.

Then there is the startup Unlimited Tomorrow. In 2020, some six years after its founding, the Rhinebeck, N.Y.-based company also rolled out a prosthetic arm courtesy of a 3D printer, while emphasizing its affordability (as low as $7,995.) compared to prosthetics produced by other means (over $50,000).

3D printers are getting ever closer to being able to produce organs, and progress is being made on other fronts as well. In 2018, researchers at the University of Utah became the first to produce ligaments and tendons in that fashion, by extracting stem cells from a patients body fat, printing them onto a layer of hydrogel, allowing time for the cells to form the required connective tissue outside the body and then implanting it where needed.

This is a particularly important breakthrough, since injuries to tendons and ligaments had in the past proven to be difficult to treat. Most commonly, tissue from cadavers was used, but there was the risk of rejection, or that the connective tissue wouldnt perform as expected.

In 2019, there was another promising development when a team at Rice University made promising strides toward producing cardiovascular networks and lung-like air sacs through the use of bioprinting technology called stereolithography apparatus for tissue engineering, or SLATE. The team hopes to commercialize that technology in the future, which could have obvious benefits for those suffering from heart or lung disease.

Truly there seem to be no bounds to what 3D printers might mean for healthcare. The possibility exists of dental professionals using the technology to create customized dental implants, prosthetics and braces that printing could be done in-office without long wait times. Once the patients teeth have been scanned, their dental treatment will be printed in-office. This allows for a better fit and even time for immediate troubleshooting. Compared to taking a mold and relying on an outside source, this is more convenient for both patients and professionals.

On the other side of the equation, a 3D printer can be used to create customized instruments for use in complex surgeries and the process can be done far more quickly than is the case by other means. It is also possible to create three-dimensional models of patients internal systems before surgical procedures, giving doctors a clear understanding of the challenges they face.

Also of interest is the production of customized medication via 3D printer, a process begun in 2015 to counter the trend toward producing dosages best-suited for white adult men, meaning women and children were receiving more than was necessary. Customizing the dosage, Multiply Labs CEO Fred Paretti told the website 3D Natives, goes a long way toward highlighting the individuality of each patient, since the error in dosage of certain active ingredients can even lead to the malfunctioning of some treatments.

The bottom line is that 3D printers will be making an even greater impact on the medical field in the years ahead, as evidenced by the fact that the number of U.S. hospitals featuring the technology grew from three in 2010 to over 100 in 2019. The need is there, and the evolution will certainly only continue. And someday, maybe there really will be a Six-Million-Dollar Man.

Photo: belekekin, Getty Images

Excerpt from:
3D medical printing making strides, and helping patients do the same - MedCity News

Read More...

Global Cord Blood Banking Industry Report 2021: Industry Trends, Expansion Technologies, Profiles of Select Cord Blood Banks and Companies -…

Thursday, January 14th, 2021

DUBLIN, Jan. 13, 2021 /PRNewswire/ -- The "Global Cord Blood Banking Industry Report 2021" report has been added to ResearchAndMarkets.com's offering.

From the early 1900s through the mid-2000s, the global cord blood banking industry proliferated with cord blood banks emerging in all major healthcare markets worldwide. From 2005 to 2010, the market reached saturation and stabilized. From 2010 to 2020, the market began to aggressively consolidate, creating both threats and opportunities within the industry.

Serious threats to the industry include low rates of utilization for stored cord blood, expensive cord blood transplantation procedures, difficulty educating obstetricians about cellular therapies, and an increasing trend toward industry consolidation. Opportunities for the industry include price efficiencies associated with scale and consolidation, accelerated regulatory pathways for cord blood and tissue-based cell therapies, and progress with ex vivo cellular expansion technologies.

Cord Blood Industry Trends

Within recent years, new themes have been impacting the industry, including the pairing of stem cell storage services with genetic and genomic testing services, as well as reproductive health services. Cord blood banks are diversifying into new types of stem cell storage, including umbilical cord tissue storage, placental blood and tissue, amniotic fluid and tissue, and dental pulp. Cord blood banks are also investigating means of becoming integrated therapeutic companies. With hundreds of companies offering cord blood banking services worldwide, the maturation of the market means that each company is fighting harder for market share.

Growing numbers of investors are also entering the marketplace, with M&A activity accelerating in the U.S. and abroad. Holding companies are emerging as a global theme, allowing for increased operational efficiency and economy of scale.Cryoholdco has established itself as the market leader within Latin America. Created in 2015, Cryoholdco is a holding company that controls over a quarter of a million stem cell units (approximately 270,000). It owns a half dozen cord blood banks, as well as a dental stem cell storage company.

Globally, networks of cord blood banks have become commonplace, with Sanpower Group establishing its dominance in Asia. Although Sanpower has been quiet about its operations, it holds 4 licenses out of only 7 issued provincial-level cord blood bank licenses in China. It has reserved over 900,000 cord blood samples in China, and its reserves amount to over 1.2 million units when Cordlife's reserves within Southeast Asian countries are included. This positions Sanpower Group and it's subsidiary Nanjing Cenbest as the world's largest cord blood banking operator not only in China and Southeast Asia but in the world.

The number of cord blood banks in Europe has dropped by more than one-third over the past ten years, from approximately 150 to under 100. The industry leaders in this market segment include FamiCord Group, which has executed a dozen M&A transactions, and Vita34, which has executed approximately a half dozen. Stemlab, the largest cord blood bank in Portugal, also executed three acquisition deals prior to being acquired by FamiCord. FamiCord is now the leading stem cell bank in Europe and one of the largest worldwide.

Cord Blood Expansion Technologies

Because cord blood utilization is largely limited to use in pediatric patients, growing investment is flowing into ex-vivocord blood expansion technologies. If successful, this technology could greatly expand the market potential for cord blood, encouraging its use within new markets, such as regenerative medicine, aging, and augmented immunity.

Currently, Gamida Cell, Nohla Therapeutics, Excellthera, and Magenta Therapeutics have ex vivo cord blood expansion products proceeding through clinical trials. Growing numbers of investors have also entered the cord blood banking marketplace, led by groups such as GI Partners, ABS Capital Partners & HLM Management, KKR & Company, Bay City Capital, GTCR, LLC, and Excalibur.

Key questions answered in this report are:

Profiles of Select Cord Blood Banks and Companies

For more information about this report visit https://www.researchandmarkets.com/r/amvb5q

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

See the original post:
Global Cord Blood Banking Industry Report 2021: Industry Trends, Expansion Technologies, Profiles of Select Cord Blood Banks and Companies -...

Read More...

Bone Therapeutics and Rigenerand sign partnership for cell therapy process development – GlobeNewswire

Thursday, January 14th, 2021

Gosselies, Belgium and Modena, Italy, 14January 2021, 7am CET BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, and Rigenerand SRL, the biotech company that both develops and manufactures medicinal products for cell therapy applications, primarily for regenerative medicine and oncology, today announce the signing of a first agreement for a process development partnership.

Allogeneic mesenchymal stem cell (MSC) therapies are currently being developed at an incredible pace and are evaluated in numerous clinical studies covering diverse therapeutic areas such as bone and cartilage conditions, liver, cardiovascular and autoimmune diseases in which MSCs could have a significant positive effect. Advances in process development to scale up these therapies could have major impacts for both their approval and commercial viability. This will be essential to bring these therapies to market to benefit patients as quickly as possible, said Miguel Forte, CEO, Bone Therapeutics. Hence, whilst Bone Therapeutics is driving on its existing clinical development programs, we have signed a first formal agreement with Rigenerand as a fellow MSC-based organization. This will result in both companies sharing extensive expertise in the process development and manufacturing of MSCs and cell and gene therapy medicinal products. Bone Therapeutics also selected Rigenerand to partner with for their additional experience with wider process development of advanced therapy medicinal products (ATMPs), including the conditioning and editing of MSCs. Rigenerand was founded by Massimo Dominici, a world opinion leader in the cell therapy with an unparalleled MSC expertise and knowledge.

The scope of collaborations between Bone Therapeutics and Rigenerand aims to focus on different aspects of product and process development for Bone Therapeutics expanding therapeutic portfolio. Rigenerand will contribute to improving the processes involved in the development and manufacture of Bone Therapeutics MSC based allogeneic differentiated cell therapy products as they advance towards patients. The first collaboration between the two organizations will initially focus on augmented professional bone-forming cells cells that are differentiated and programmed for a specific task. There is also potential for Bone Therapeutics to broaden its therapeutic targets and explore new mechanisms of action with potential gene modifications for its therapeutic portfolio.

In addition to Rigenerands MSC expertise, Bone Therapeutics also selected Rigenerand as a partner for Rigenerands GMP manufacturing facility. This facility, situated in Modena, Italy, has been designed to host a number of types of development processes for ATMPs. These include somatic, tissue engineered and gene therapy processes. These multiple areas of Rigenerand capabilities enable critical development of new processes and implementation of the gene modification of existing processes. In addition, Rigenerand has built considerable experience in cGMP manufacturing of MSC-based medicinal products, including those that are genetically modified.

Process development and manufacturing is a key part of the development for ATMPs internationally. Navigating these therapies through the clinical development phase and into the market requires a carefully considered process development pathway, said Massimo Dominici, scientific founder, Rigenerand, professor of medical oncology, and former President of the International Society for Cell & Gene Therapy (ISCT). This pathway needs to be flexible, as both the market and materials of these therapies continues to evolve alongside an improved clinical efficacy.

Rigenerand will offer considerable input from its experience of MSC-based therapies to enable Bone Therapeutics to keep and further accelerate the pace in development of the product processes of its MSC based allogeneic differentiated cell therapy as they advance towards patients, said Giorgio Mari, CEO, Rigenerand. We will continue to use our MSC expertise in the development of Rigenerands own products, as well as in process development and manufacturing cell and gene therapies for partner organizations across the globe.

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and other diseases. The Company has a, diversified portfolio of cell and biologic therapies at different stages ranging from pre-clinical programs in immunomodulation to mid-to-late stage clinical development for orthopedic conditions, targeting markets with large unmet medical needs and limited innovation.

Bone Therapeutics is developing an off-the-shelf next-generation improved viscosupplement, JTA-004, which is currently in Phase III development for the treatment of pain in knee osteoarthritis. Consisting of a unique combination of plasma proteins, hyaluronic acid - a natural component of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain and inflammation. Positive Phase IIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement.

Bone Therapeutics core technology is based on its cutting-edge allogeneic cell therapy platform with differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs) which can be stored at the point of use in the hospital. Currently in pre-clinical development, BT-20, the most recent product candidate from this technology, targets inflammatory conditions, while the leading investigational medicinal product, ALLOB, represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells. These cells are produced via the Bone Therapeutics scalable manufacturing process. Following the CTA approval by regulatory authorities in Europe, the Company has initiated patient recruitment for the Phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process. ALLOB continues to be evaluated for other orthopedic indications including spinal fusion, osteotomy, maxillofacial and dental.

Bone Therapeutics cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available at http://www.bonetherapeutics.com.

About Rigenerand

Rigenerand SRL is a biotech company that both develops and manufactures medicinal products for cell therapy applications, primarily for regenerative medicine and oncology and 3D bioreactors as alternative to animal testing for pre-clinical investigations.

Rigenerand operates through three divisions:

Rigenerand is developing RR001, a proprietary ATMP gene therapy medicinal product for the treatment of pancreatic ductal adenocarcinoma (PDAC). RR001 has been granted an Orphan Drug Designation (ODD) by US-FDA and from the European Medicine Agency. The Clinical trial is expected to start in Q2 2021.

Rigenerand is headquartered in Medolla, Modena, Italy, with more than 1,200 square metres of offices, R&D and quality control laboratories and a cell factory of 450 square metres of sterile cleanroom (EuGMP Grade-B) with BSL2/BSL3 suites for cell and gene therapies manufacturing. It combines leaders and academics from biopharma and medical device manufacturing sectors.

For further information, please contact:

Bone Therapeutics SAMiguel Forte, MD, PhD, Chief Executive OfficerJean-Luc Vandebroek, Chief Financial OfficerTel: +32 (0)71 12 10 00investorrelations@bonetherapeutics.com

For Belgian Media and Investor Enquiries:BepublicCatherine HaquenneTel: +32 (0)497 75 63 56catherine@bepublic.be

International Media Enquiries:Image Box CommunicationsNeil Hunter / Michelle BoxallTel: +44 (0)20 8943 4685neil.hunter@ibcomms.agency / michelle@ibcomms.agency

For French Media and Investor Enquiries:NewCap Investor Relations & Financial CommunicationsPierre Laurent, Louis-Victor Delouvrier and Arthur RouillTel: +33 (0)1 44 71 94 94bone@newcap.eu

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such persons officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Excerpt from:
Bone Therapeutics and Rigenerand sign partnership for cell therapy process development - GlobeNewswire

Read More...

Europe Prescription Spectacles Market to Exhibit a 5.2% CAGR and Reach USD 31.89 Billion by 2027; Increasing Incidence of Ocular Disorders to Favor…

Thursday, January 14th, 2021

Pune, India, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The Europe prescription spectacles market size is expected to reach USD 31.89 billion by 2027 while exhibiting a CAGR of 5.2% between 2020 and 2027. This is attributable to the increasing prevalence of ocular disorders and the growing adoption of mobile phones and laptops that drive the demand for innovative prescription spectacles in Europe. This information is published by Fortune Business Insights, in its latest report. The report further mentions that the market stood at USD 23.92 billion in 2019.

Closure of Shops to Lead to Declining Sales in the Global Market for Europe Prescription Spectacles

Several European countries are under lockdown owing to the widespread effects of the global pandemic that has taken several lives and many more under quarantine in the region. This has led to the closure of several industrial operations and other activities. Additionally, the postponement of optical surgical procedures, closure of optics, and other factors have led to reduced generation of sales revenue that is affecting the market negatively. However, adoption of advanced technology such as telemedicine, and the growing focus on sales through online channels will favor the market growth in the forthcoming years.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/europe-prescription-spectacles-market-104521

Prescription spectacles are used to correct refractive error in the person and further aids in improving his poor vision. The increasing rate of people suffering from impaired vision is due to several factors such as hyperopia, myopia, and presbyopia among the people that drives the demand for innovative Europe prescription spectacles range.

Increasing Incidence of Ocular Disorder to Augment Growth

According to the report by the European Blind Union, it is estimated that around 30 million people in Europe suffer from blindness and partial sightedness. That is about 1 in 30 Europeans experiencing vision loss. The increasing prevalence of ocular disorder amongst the population is propelling the manufacturers to boost the Europe prescription spectacles sale by introducing innovative products. Moreover, the growing adoption of mobiles and laptops owing to the increasing work from culture amid COVID-19 is expected to contribute to the Europe prescription spectacles market growth during the forecast period.

Click here to get the short-term and long-term impact of COVID-19 on this Market.Please visit: https://www.fortunebusinessinsights.com/europe-prescription-spectacles-market-104521

More Than 55 Years Segment Held 43.4% Market Share in 2019

The more than 55 years segment, based on age group, held a market share of about 43.4% in 2019 and is likely to dominate the global market for the Europe prescription spectacles in the forthcoming years. This is ascribable to factors such as the presence of a higher proportion of the population coming under this age bracket in Europe.

Germany to Remain Dominant; Increasing Consumer Spending Capacity to Aid Growth

Among all the countries, Germany stood at USD 5.24 billion in the year 2019 and is expected to hold the highest position in the Europe prescription eyeglasses market. This is attributable to the increasing consumer spending capacity of the working population that is driving the sales in the Europe prescription spectacles stores.

The market in Italy is expected to showcase significant growth backed by the large presence of major eye wear giants in the country that are contributing to the high sales of the Europe prescription eyeglasses between 2020 and 2027.

Quick Buy - Europe Prescription Spectacles Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/104521

Carl Zeiss Announces New ZEISS UVClean Technology to Maintain its Dominance

The Europe prescription spectacles market is fragmented by the presence of major companies that are focusing on introducing innovative eye gear technology to surge the Europe prescription spectacles demand. For instance, in September 2020, Carl Zeiss Meditec AG, a leading spectacle provider, announced the launch of ZEISS UVClean technology device. As per the company, it is an optometry-specific UV-C disinfecting device that is designed for eye care professionals.

Industry Development:

List of the Companies Profiled in the Market for Europe Prescription Spectacles:

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/europe-prescription-spectacles-market-104521

Table of Contents:

TOC Continued.!

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/europe-prescription-spectacles-market-104521

SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:

Have a Look at Related Reports:

Active Wound Care Market Share and Global Trend by Product Type (Biological Skin Equivalents, Growth Factors, Biological Dressings), Indication (Diabetic Foot Ulcers, Pressure Ulcers, Lower Limb Ulcers), End User (Hospitals, Clinics, Home Care Settings) and Geography Forecast till 2025

Orthobiologics Market Share and Global Trend by Product Type (Viscosupplements, Bone Growth Stimulators, Demineralized Bone Matrix, Synthetic Bone Substitutes, Stem Cells, Allografts), Application (Spinal Fusion, Maxillofacial & Dental, Soft Tissue Repair, Reconstructive & Fracture Surgery), End User (Hospitals, Ambulatory Surgical Centers, Speciality Clinics) and Geography Forecast till 2025

X-Ray Flat Panel Detectors Market Share and Global Trend by Product Type (Amorphous, Silicon, Amorphous Selenium, Complementary Metal Oxide Semiconductor), Imaging type (Static, Dynamic), Type (Retrofit, New), Application (General Radiography, Dentistry, Oncology, Orthopedic) Geography Forecast till 2026

Bone Growth Stimulators Market Share and Global Trend By Product Type (Bone Growth Stimulation Devices, Bone Morphogenetic Proteins (BMP), Platelet-Derived Growth Factor (PDGF)), By Application (Spinal Fusion, Maxillofacial & Dental, Nonunion and Union Bone Fractures), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Home Care), and Geography Forecast till 2026

Veterinary Drugs Market Share and Global Trend by By Product (Anti-infectives, Anti-inflammatory, Parasiticides, Others), By Animal (Companion, Livestock), By Route of Administration (Oral, Parenteral,Topical), Distribution Channel (Veterinary Hospitals, Veterinary Clinics, Pharmacies & Drug Stores, Others,) and Geography Forecast till 2025

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/europe-prescription-spectacles-market-10369

See more here:
Europe Prescription Spectacles Market to Exhibit a 5.2% CAGR and Reach USD 31.89 Billion by 2027; Increasing Incidence of Ocular Disorders to Favor...

Read More...

Priming the Immune System to Fight Cancer – PRNewswire

Thursday, December 17th, 2020

PHILADELPHIA, Dec. 17, 2020 /PRNewswire/ --Immunotherapies, such as checkpoint inhibitor drugs, have made worlds of difference for the treatment of cancer. Most clinicians and scientists understand these drugs act on what's known as the adaptive immune system, the T cells and B cells that respond to specific threats to the body.

New research from a team co-led by Penn Dental Medicine's George Hajishengallis suggests that the innate immune system, which responds more generally to bodily invaders, may be an important yet overlooked component of immunotherapy's success.

Their work, published in the journal Cell, found that "training" the innate immune system with -glucan, a compound derived from fungus, inspired the production of innate immune cells, specifically neutrophils, that were programmed to prevent or attack tumors in an animal model.

"The focus in immunotherapy is placed on adaptive immunity, like checkpoint inhibitors inhibit the interaction between cancer cells and T cells," says Hajishengallis. "The innate immune cells, or myeloid cells, have not been considered so important. Yet our work suggests the myeloid cells can play a critical role in regulating tumor behavior."

The current study builds on earlier work by Hajishengallis and a multi-institutional team of collaborators, which showed that trained immunity, elicited through exposure to the fungus-derived compound -glucan, could improve immune recovery after chemotherapy in a mouse model.

In that previous study, the researchers also showed that the "memory" of the innate immune system was held within the bone marrow, in hematopoietic stem cells that serve as precursors of myeloid cells, such as neutrophils, monocytes, and macrophages.

The team next wanted to get at the details of the mechanism by which this memory was encoded. "The fact that -glucan helps you fight tumors doesn't necessarily mean it was through trained immunity," says Hajishengallis.

To confirm that link, the researchers isolated neutrophils from mice that had received the innate immune training via exposure to -glucan and transferred them, along with cells that grow into melanoma tumors, to mice that had not received -glucan. Tumor growth was significantly dampened in animals that received cells from mice that had been trained.

-glucan is already in clinical trials for cancer immunotherapy, but the researchers say this finding suggests a novel mechanism of action with new treatment approaches.

"This is a breakthrough concept that can be therapeutically exploited for cancer immunotherapy in humans," Hajishengallis says, "specifically by transferring neutrophils from -glucan-trained donors to cancer patients who would be recipients."

Contact: Beth Adams, [emailprotected]

SOURCE Penn Dental Medicine

http://www.dental.upenn.edu

View original post here:
Priming the Immune System to Fight Cancer - PRNewswire

Read More...

Girl gets her smile back – and a new jaw – thanks to innovative tissue engineering procedure – Newswise

Thursday, December 17th, 2020

Newswise Nine-year-old Grace Moss of Laredo, Texas, was facing a daunting prospect. A tumor that had invaded her jaw had been removed, but now the plastic surgeon wanted to remove her fibula - the smaller of the two bones in her lower leg - to use as a graft.

"When I got the news that the next surgery was going to be a graft of a bone from her leg, I started thinking, 'There has to be another option. Grace is just an active little girl I don't want to take that away from her," said Dwayne Moss, Grace's dad.

Fortunately, he discovered an article featuring someone at The University of Texas Health Science Center at Houston (UTHealth) who could provide Grace with a high-tech treatment option - her own stem cells.

But the road to that help would be a long one. Grace's ordeal began at a regular dental checkup in her hometown in June 2016, when her dentist noticed what looked like a cyst on her lower right jaw, and referred her to a surgeon in San Antonio.

"We couldn't get an appointment with him so we actually drove up to San Antonio and went to the hospital when he was doing rounds. We thought we were just going to see him and go home but we were admitted and the very next day they did a biopsy," Moss said.

The pathology results came back in August 2016. It wasn't a cyst on Grace's jaw but an ameloblastoma, a benign, but aggressive, localized tumor.

In October 2016, the tumor was removed, along with a third of her jaw bone, and a titanium bar and spacer were placed to support the mouth from the hinge to the jaw.

"The doctor removed the tumor with minimal margins, so he wanted to wait six months before performing her next surgery to make sure the tumor didn't return. The next surgery was supposed to be a bone graft taking Grace's fibula and using that to construct a new jaw," Moss said.

Those six months gave Moss the opportunity to see what other options existed for his daughter. He started researching and came across a journal article featuring James Melville, DDS, associate professor of oral and maxillofacial surgery at UTHealth School of Dentistry.

Moss reached out to Melville about a month before the scheduled bone graft surgery.

"When Dr. Melville responded to my email I was like, 'Oh wow, there's hope!'" Moss said.

Melville reconstructed Grace's jaw using tissue engineering. Stem cells from Grace's hip were placed in a centrifuge to concentrate them, and then combined with bone morphogenic protein and bone donated from another source to create a bone graft just like the one that would have come from her leg.

"It's regenerative medicine and the jaw bone Grace has now was completely regenerated from cells taken from within her own body. In my opinion, it's the next step in medicine," Melville said.

UTHealth is a pioneer in this type of procedure.

"We are one of only two institutions that perform this procedure and I have personally performed over 100 of them," Melville said, who added that several studies have been published about the procedure.

Three years later, Grace is now a healthy 12-year-old girl leading a normal, active life and is able to play softball, basketball, and volleyball, and run track and field. She wants to tell everyone her story with the hope that it can help someone else going through something similar.

"I want to be able to help people who don't know how to feel when they get a diagnosis like this. They might be scared, confused, and hopeless, but they aren't alone," Grace said.

Moss is incredibly proud of Grace for sharing her story. "Helping people is right up her alley," he said.

For Melville, it's all about the look Grace has on her face whenever she walks into his office.

"The best thing for me is that she got her smile back," he said.

View post:
Girl gets her smile back - and a new jaw - thanks to innovative tissue engineering procedure - Newswise

Read More...

Bone Regeneration Material Market: Cell-based Segment to Expand Significantly – BioSpace

Thursday, December 17th, 2020

Bone Regeneration Material Market: Introduction

Bone-regeneration techniques, either with autografts or allografts, represent a challenge for reconstructive surgery. Biomaterials are temporary matrices for bone growth and provide a specific environment and architecture for tissue development. Depending on the specific intended application of the matrix, whether for structural support, drug-delivery capability, or both, certain material categories may be more or less well suited to the final structure.

Read Report Overview - https://www.transparencymarketresearch.com/bone-regeneration-material-market.html

Key Drivers and Restraints of Global Bone Regeneration Material Market

Increase in prevalence of degenerative joint diseases boost the market. Worldwide estimates of degenerative joint diseases indicate that 9.6% men and 18.0% women above 60 years have symptomatic osteoarthritis. According to expert opinions presented in the EULAR committee report, radiographic evidence of knee osteoarthritis in men and women over 65 years of age is found in 30% of the population.

In the absence of disease modifying therapy, a large number of patients with osteoarthritis progress to advance joint destruction. Surgery with bone grafts and substitutes play a major role in the management of osteoarthritis to avoid advanced joint destruction. According to the American College of Rheumatology, advances in biomaterial and tissue engineering are expected to create new opportunities to integrate surgical approaches in osteoarthritis.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=80488

Increase in the number of orthopedic surgeries also fuels the market. According to the American Academy of Orthopaedic Surgeons (AAOS), approximately 129,000 total knee arthroplasty (TKA) surgeries were performed in the U.S. in 1990, and the number has increased to over 600,000 in 2010. The AAOS has projected that 3 million TKA procedures would be performed by 2030 in the U.S. alone. Moreover, spinal surgeries are becoming increasingly popular, and approximately 432,000 spinal fusions are performed in the U.S. each year. Bone grafts and substitutes are extensively used for the surgeries mentioned above. This is likely to fuel the bone regeneration material market.

Bone graft and substitutes are a long-term solution to bone problem treatment; however, these are expensive. No two patients or their customized bone grafts and substitutes treatments are exactly alike. Hence, the number of appointments, procedures, and costs vary accordingly. Surgeons charge US$ 35,000 to US$ 40,000 for a complex posterolateral lumbar spine fusion bone graft surgery. Most surgeons refer patients to specialty surgeons, neurologists, or orthopedic physicians, which increases the cost of procedure. Asia is price-sensitive and displays inhibitions with respect to investing in bone graft and substitutes, which are often only affordable to the elite population; therefore offering a comparatively smaller market.

Request for Analysis of COVID-19 Impact on Bone Regeneration Material Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=80488

Cell-based Segment to Expand Significantly

Based on product type, the global bone regeneration material market can be divided into ceramic-based, polymer-based, growth factor-based, cell-based and others

The ceramic-based segment dominated the global market in 2019. It is projected to sustain its position during the forecast period. Ceramic-based bone grafts are widely used to reduce the need for iliac crest bone grafting. Rise in geriatric population with oral health issues across the world has augmented the number of bone graft surgeries performed in the last few years.

However, the cell based segment is projected to expand at a notable CAGR during the forecast period. Bone tissue engineering (BTE) using bone marrow stem cells has been suggested as a promising technique for reconstructing bone defect in order to overcome the drawbacks of bone graft materials.

Orthopedic surgery segment to dominate global bone regeneration material market

Based on application, the global bone regeneration material market can be segregated into orthopedic surgery, bone trauma, dental surgery and others.

In terms of revenue, the orthopedic surgery segment accounted for a prominent share of the market in 2019 owing to a rise in the geriatric population and increase in cases of orthopedic diseases. According to WHO, between 2015 and 2050, the proportion of the world's population over 60 years would nearly double from 12% to 22%. The number of people aged 60 years and older is estimated to outnumber children younger than 5 years by 2020. As per MVZ Gelenk-Klinik data, more than 2400 orthopedic surgical procedures are performed per year at the Gelenk Klinik Orthopaedic Hospital.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=80488

North America to dominate global bone regeneration material market

In terms of region, the global bone regeneration material market can be divided into: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

North America accounted for a significant share of the bone regeneration material market in 2019, followed by Europe. Usage of new and innovative products in both premium and value segments among various bone grafts substitutes is projected to boost the bone regeneration material market in several countries in Europe and North America in the next few years. According to the Centers for Disease Control and Prevention (CDC), the total number of inpatient surgeries carried out in the U.S. were 51.4 million in 2014; of these 719,000 were total knee replacements and 332,000 were total hip replacement.

The market in developing countries in Asia Pacific is estimated to expand at a significant CAGR during the forecast period. The market in Asia Pacific is driven by an increase in population and time taken to accept new technologies. Increase in the number of patients and geriatric population are major factors that are expected to propel the market in Japan during the forecast period. According to the Gerontological Society of America, Japan has the highest proportion of geriatric population in the world. Hence, demand for orthopedic surgeries is estimated to be higher in Japan than that in other countries in Asia Pacific.

Pre Book Bone Regeneration Material Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=80488&ltype=S

Key Manufacturers Operating in Market

The global bone regeneration material market was highly fragmented in 2019. Key manufacturers operating in the global market are:

Browse More Trending Reports by Transparency Market Research:

Tactile Imaging Market: https://www.transparencymarketresearch.com/tactile-imaging-market.html

Eye Stent Market: https://www.transparencymarketresearch.com/eye-stent-market.html

Podiatry Workstations Market: https://www.transparencymarketresearch.com/podiatry-workstations-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

See more here:
Bone Regeneration Material Market: Cell-based Segment to Expand Significantly - BioSpace

Read More...

Stem Cell Therapy Market is estimated to be worth USD 8.5 Billion by 2030, claims Roots Analysis – Cheshire Media

Saturday, November 28th, 2020

With multiple approved products, the field of stem cell therapies has gained substantial momentum over the last decade; several innovator companies are currently progressing their proprietary therapy candidates with cautious optimism. In fact, recent studies suggest that mesenchymal stem cells have the potential to end the Coronavirus (COVID-19) pandemic.

Roots Analysis is pleased to announce the publication of its recent study, titled, Global Stem Cells Market: Focus on Clinical Therapies, 20202030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent)).

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Source of Stem Cell

Origin of Stem Cell

Type of Stem Cell

Lineage of Stem Cell

Route of Administration

Therapeutic Area

End Users

Key Geographical Regions

Transcripts of interviews held with the following senior level representatives of stakeholder companies

Key companies covered in the report

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If youd like help with your growing business needs, get in touch at [emailprotected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[emailprotected]

Follow this link:
Stem Cell Therapy Market is estimated to be worth USD 8.5 Billion by 2030, claims Roots Analysis - Cheshire Media

Read More...

Global Regenerative Medicine Market 2020-2025: Opportunities with the Implementation of the 21st Century Cures Act – Stockhouse

Saturday, November 28th, 2020

Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The "Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The Global Regenerative Medicine Market is Projected to Reach USD 17.9 Billion by 2025 from USD 8.5 Billion in 2020, at a CAGR of 15.9% during the Forecast Period.

Market growth is driven by the rising prevalence of chronic diseases, genetic disorders, and cancer; rising investments in regenerative medicine research; and the growing pipeline of regenerative medicine products. However, the high cost of cell and gene therapies and ethical concerns related to the use of embryonic stem cells in research and development are expected to restrain the growth of this market during the forecast period.

The cell therapies segment accounted for the highest growth rate in the regenerative medicine market, by product, during the forecast period

Based on products, the regenerative medicine market is segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies. The cell therapies segment accounted for the highest growth rate in the regenerative medicine market in 2019. The increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders and the rising funding for the R&D of regenerative medicine products and therapies are the major factors driving the growth of this segment.

Oncology segment accounted for highest CAGR

Based on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications. In 2019, the oncology segment accounted for the highest growth rate. This can be attributed to the rising prevalence of orthopedic diseases, growing geriatric population, increasing number of stem cell research projects, growing number of clinical researches/trials, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders.

Europe: The fastest-growing region regenerative medicine market

The global regenerative medicine market is segmented into North America, Europe, the Asia Pacific, and Rest of the World. The North America region is projected to grow at the highest CAGR during the forecast period in 2019. The growth in the North American regenerative medicine market can be attributed to rising stem cell banking, tissue engineering, and drug discovery in the region; expansion of the healthcare sector; and the high adoption of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases.

Market Dynamics

Drivers

Restraints

Opportunities

Impact of the COVID-19 Pandemic on the Regenerative Medicine Market

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/6v7acf

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See the original post here:
Global Regenerative Medicine Market 2020-2025: Opportunities with the Implementation of the 21st Century Cures Act - Stockhouse

Read More...

Molecular Diagnostics Market to Record over 7% Growth Rate and Hit USD 13873.6 Million by 2025; Advancements in this Field to Increase Productivity…

Saturday, November 28th, 2020

Pune, India, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Global Molecular Diagnostics Market covered a value of USD 8012.7 Million in the year 2017 and is projected to reach USD 13873.6 Million by 2025. As per the report, the global market is expected to garner a healthy CAGR of 7.1% throughout the forecast period. The global molecular diagnostics market is projected to grow with rising technological developments in molecular diagnostic techniques. These advancements are intended to offer higher accuracy, cost-effectiveness, and portability which further drives the market. This information was published by Fortune Business Insights in a report. In 2017, North America market was valued at US$ 3639.4 Mn and is likely to lead the global landscape through the forecast period. The rising collaborations and association between research hospitals and academic institutions encourages growth of the market in this region.

Molecular Diagnostic Industry Developments:

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/molecular-diagnostics-market-100086

Infectious Diseases: The Largest Growing Segment Among Other Applications

Among applications, infectious diseases segment is expected to account for a majority of share in the global molecular diagnostic market. The scope of this segment is increasing owing to the rising number of patients suffering from infections and microbial outbreaks. Moreover, the infectious diseases segment covered a share of 60% in the year 2017.

Development of tests for several diseases and rising awareness about the benefits of adopting molecular diagnostic technologies may prevent the occurrence of infectious diseases. Global organizations such as World Bank and the World Health Organization (WHO) are planning to conduct awareness programs to increase the talent pool for molecular diagnostics.

Click here to get the short-term and long-term impact of COVID-19 on this market.

Please visit: https://www.fortunebusinessinsights.com/industry-reports/molecular-diagnostics-market-100086

North America Continues to Maintain Its Stronghold until 2025

"Well-established healthcare infrastructure, combined with the rising incidence of cancer is helping the market grow in North America," stated a lead analyst at Fortune Business Insights. "Developed healthcare systems further helps in the easy availability and accessibility of advanced instruments such as molecular diagnostics.

In 2017, this regional market was valued at US$ 3639.4 Mn and is likely to lead the global landscape through the forecast period. The rising collaborations and association between research hospitals and academic institutions encourages growth of the market in this region. Both the bodies are involving in continuous discussions for process improvements in molecular diagnosis.

The market in Europe is also expected to witness considerable growth with growing emphasis on clinical microbiology and hospital research organizations. This is mainly done to increase the number of molecular diagnostic techniques. Rapidly developing healthcare infrastructure and rising investments in research and development activities are factors responsible for creating good growth opportunities.

Quick Buy - Molecular Diagnostics Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100086

Abbott Launched a Next Generation System Used for Molecular Diagnosis

The global molecular diagnostics market is expected to be dominated by companies such as Danaher, Abbott, QIAGEN, and F. Hoffmann-La Roche Ltd. Strong supply chain network, rising research and development (R&D) activities, and development strategies are likely to create growth opportunities for the above companies.

In 2016, Abbott announced the introduction of a next-generation system called Alinity. This system is used for plasma and blood screening, haematology procedures, molecular diagnostics, and clinical chemistry. Companies are focussing on to develop new molecular diagnostic tests, which may foster growth of the market.

In 2018, Banyan Biomakers received marketing authorization from the U.S. FDA on its first blood diagnostic test. This test was developed to treat traumatic brain injuries which is also referred to as concussion among adults. These developments are likely to have a positive impact on the overall market.

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/molecular-diagnostics-market-100086

Molecular Diagnostic Market Players:

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/molecular-diagnostics-market-100086

Molecular Diagnostic Market Segmentations:

By Product Type

Instruments

Reagents & Consumables

By Application

Infectious Disease

Blood Screening

Histology

Oncology

Others

By Technique

Amplification Techniques

Hybridization Techniques

Sequencing Techniques

Others

By End User

Hospitals

Clinical & Pathology Labs

Others

By Geography

North America (USA and Canada)

Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

Latin America (Brazil, Mexico and Rest of Latin America)

Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

SECONDARY DATA SOURCES THAT WE REFER TO:

SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:

Have a Look at Related Reports:

Active Wound Care Market Share and Global Trend by Product Type (Biological Skin Equivalents, Growth Factors, Biological Dressings), Indication (Diabetic Foot Ulcers, Pressure Ulcers, Lower Limb Ulcers), End User (Hospitals, Clinics, Home Care Settings) and Geography Forecast till 2025

Orthobiologics Market Share and Global Trend by Product Type (Viscosupplements, Bone Growth Stimulators, Demineralized Bone Matrix, Synthetic Bone Substitutes, Stem Cells, Allografts), Application (Spinal Fusion, Maxillofacial & Dental, Soft Tissue Repair, Reconstructive & Fracture Surgery), End User (Hospitals, Ambulatory Surgical Centers, Speciality Clinics) and Geography Forecast till 2025

X-Ray Flat Panel Detectors Market Share and Global Trend by Product Type (Amorphous, Silicon, Amorphous Selenium, Complementary Metal Oxide Semiconductor), Imaging type (Static, Dynamic), Type (Retrofit, New), Application (General Radiography, Dentistry, Oncology, Orthopedic) Geography Forecast till 2026

Bone Growth Stimulators Market Share and Global Trend By Product Type (Bone Growth Stimulation Devices, Bone Morphogenetic Proteins (BMP), Platelet-Derived Growth Factor (PDGF)), By Application (Spinal Fusion, Maxillofacial & Dental, Nonunion and Union Bone Fractures), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Home Care), and Geography Forecast till 2026

Veterinary Drugs Market Share and Global Trend by By Product (Anti-infectives, Anti-inflammatory, Parasiticides, Others), By Animal (Companion, Livestock), By Route of Administration (Oral, Parenteral,Topical), Distribution Channel (Veterinary Hospitals, Veterinary Clinics, Pharmacies & Drug Stores, Others,) and Geography Forecast till 2025

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/molecular-diagnostics-market-9028

View original post here:
Molecular Diagnostics Market to Record over 7% Growth Rate and Hit USD 13873.6 Million by 2025; Advancements in this Field to Increase Productivity...

Read More...

North America Tissue Engineering Market Report 2020: Market is Expected to Reach US$12.23 Billion by 2027 from US$4.45 Billion in 2019 -…

Sunday, November 22nd, 2020

DUBLIN--(BUSINESS WIRE)--The "North America Tissue Engineering Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Material Type, Applications, and Country" report has been added to ResearchAndMarkets.com's offering.

The North America tissue engineering market is expected to reach US$ 12,230.37 million by 2027 from US$ 4,456.95 million in 2019; it is estimated to grow at a CAGR of 13.8% during 2020-2027.

The market growth is primarily attributed to the increasing incidences of chronic diseases, road accidents, and trauma injuries, and technological advancements in 3D tissue engineering techniques. High cost associated to the tissue engineering process is one of the major factors restraining the growth of the market. Additionally, increasing financial contributions by government and private sector are likely to fuel the growth of the North America tissue engineering market during the forecast period.

Tissue engineering is a blend of material methods and cellular activities. This approach involves the use of physicochemical and biochemical attributes of humans to replace the biological tissues and strengthen them. It is an innovative technology that works either separately or in conjunction with scaffolds, stem cells, regenerative medicine, and growth factors or negotiators. The process utilizes molecular and cellular processes in combination with the principles of material engineering to surgically repair and restore tissue.

According to the US Centers of Medicare and Medicaid, more than 900 million surgeries are performed for bone reconstruction or replacement. This has resulted in urgent need for increasing the grants and funding for tissue engineering; government funding for the ongoing research for tissue regeneration is a major driver for market growth in North America. According to the National Institutes of Health (NIH) funding study in 2018 , the research studies related with tissue engineering and regenerative medicines in US has received funding of USD 1.8 and USD 1.0 billion, respectively.

The US government is also encouraging innovation in healthcare through funding and establishing manufacturing hubs. For instance, in 2014, the National Institutes of Health established a 3D bioprinting Exchange to promote open-source sharing of biomaterial and other technologies used in tissue engineering.

Moreover, the US FDA currently approves dental, orthopedics, and craniomaxillary tissue engineering products, and the expected approvals for other tissue engineered products in other therapeutic segments would also offer significant opportunities in the North America market. In 2019, Aspect Biosystems (Canada) collaborated with the National Research Council of Canada to develop a new tissue engineered therapeutic model for the treatment of various central nervous system diseases, including Alzheimer's disease.

In the US, due to an increasing number of COVID-19 infected patients, healthcare professionals and leading organizations are rechanneling the flow of healthcare resources from R&D to primary care, which is slowing down the process of innovation. Further, the COVID-19 pandemic is also hindering the conduct of clinical trials and drug development, and the operations of diagnostic industry in the US.

For instance, Stryker Corporation, a well-known player in the tissue engineering industry, has diverted operations to manufacture COVID-19 diagnostics and PPE kits. Moreover, according to a recent survey by Medscape in July 2020, substantial disruption has been witnessed in routine research activities that include tissue engineering and regenerative medicines as a result of the COVID-19 pandemic. The rapid increase in the number of the infected patients in the US and Canada is likely to result in the slowdown of the market growth in the near future.

In 2019, the biologically derived material segment accounted for the largest share of the North America tissue engineering market. The growth of the market for this segment is attributed to the rising adoption of biomaterials due to their natural regenerative potential to restore tissue functioning and ability to facilitate the on demand release of chemokines with this procedure. Further, the synthetic material segment is likely to register the highest CAGR in the market during the forecast period.

Key Topics Covered:

1. Introduction

2. North America Tissue Engineering Market - Key Takeaways

3. Research Methodology

4. North America Tissue Engineering Market - Market Landscape

4.1 Overview

4.2 PEST Analysis

4.3 Expert Opinion

5. North America Tissue Engineering Market - Key Market Dynamics

5.1 Key Market Drivers

5.1.1 Increasing incidences of chronic diseases, road accidents and traumatic injuries.

5.1.2 Technological Advancements in the Field of 3D Tissue Engineering

5.1.3 Increasing government and Private sectors funding

5.2 Key Market Restraints

5.2.1 High Cost of Treatment Options Involving Tissue Engineering

5.3 Impact Analysis

6. Tissue Engineering Market - North America Analysis

6.1 North America Tissue Engineering Market Revenue Forecasts and Analysis

7. North America Tissue Engineering Market Analysis - By Material Type

7.1 Overview

7.2 North America Tissue Engineering Market, By Material Type 2019-2027 (%)

7.2.1 North America Tissue Engineering Market Devices Revenue and Forecasts to 2027, By Material Type (US$ Mn)

7.3 Biologically Derived Material

7.3.1 Overview

7.3.2 North America Biologically Derived Material Market Revenue and Forecasts to 2027 (US$ Mn)

7.4 Synthetic material

7.5 Others

8. North America Tissue Engineering Market Analysis - By Application

8.1 Overview

8.2 North America Tissue Engineering Market, By Application 2019-2027 (%)

8.2.1 North America Tissue Engineering Market Revenue and Forecasts to 2027, By Application (US$ Mn)

8.3 Orthopedic, Musculoskeletal & Spine

8.3.1 Overview

8.3.2 North America Orthopedic, Musculoskeletal & Spine: Tissue Engineering Market Segment Revenue and Forecasts to 2027 (US$ Mn)

8.4 Neurology

8.5 Cardiology & Vascular

8.6 Skin

8.7 Other

9. Tissue Engineering Market Revenue and Forecasts To 2027 - Regional Analysis

10. Impact of COVID-19 Pandemic on North America Tissue Engineering Market

10.1 North America: Impact Assessment of COVID-19 Pandemic

11. Company Profiles

11.1 Key Facts

11.2 Business Description

11.3 Products and Services

11.4 Financial Overview

11.5 SWOT Analysis

11.6 Key Developments

For more information about this report visit https://www.researchandmarkets.com/r/x7afv7

Excerpt from:
North America Tissue Engineering Market Report 2020: Market is Expected to Reach US$12.23 Billion by 2027 from US$4.45 Billion in 2019 -...

Read More...

Latest Study explores the Stem Cell Banking Market Witness Highest Growth in nea – GroundAlerts.com

Thursday, November 5th, 2020

The ' Stem Cell Banking market' research report now available with Market Study Report, LLC, is a compilation of pivotal insights pertaining to market size, competitive spectrum, geographical outlook, contender share, and consumption trends of this industry. The report also highlights the key drivers and challenges influencing the revenue graph of this vertical along with strategies adopted by distinguished players to enhance their footprints in the Stem Cell Banking market.

The latest research report on the Stem Cell Banking market assesses the major factors influencing industry growth with respect to the competitive dynamics and geographical reach. It also ensembles the challenges prevalent in this industry vertical and identifies opportunities that will further aid business expansion. Further, the report revisits all areas of the business to cover the impact of COVID-19 pandemic so as to assist stakeholders in devising new strategies and reinforcing their position in the market.

Request a sample Report of Stem Cell Banking Market at:https://www.marketstudyreport.com/request-a-sample/2953678?utm_source=Groundalerts.com&utm_medium=AN

Key pointers from COVID-19 impact analysis:

Important inclusions in the Stem Cell Banking market report:

Ask for Discount on Stem Cell Banking Market Report at:https://www.marketstudyreport.com/check-for-discount/2953678?utm_source=Groundalerts.com&utm_medium=AN

Regional scope:

TOC of Stem Cell Banking Market Report Includes:

The Report Answers the key Questions

For More Details On this Report: https://www.marketstudyreport.com/reports/global-stem-cell-banking-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Related Reports:

1. Global Multiple Myeloma Drugs Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-multiple-myeloma-drugs-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

2. Global Animal Hospitals and Veterinary Clinics Services Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-animal-hospitals-and-veterinary-clinics-services-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Related Report : https://www.marketwatch.com/press-release/oat-milk-market-size-to-witness-huge-growth-by-2026-2020-11-05?tesla=y

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Continued here:
Latest Study explores the Stem Cell Banking Market Witness Highest Growth in nea - GroundAlerts.com

Read More...

Stem Cell Therapy Market is estimated to be worth USD 8.5 Billion by 2030 – PRnews Leader

Thursday, November 5th, 2020

The success of approved stem cell therapies has caused a surge in interest of biopharma developers in this field; many innovator companies are currently progressing proprietary leads across different phases of clinical development, with cautious optimism

Roots Analysis has announced the addition of Global Stem Cells Market: Focus on Clinical Therapies, 20202030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent)) report to its list of offerings.

There is a growing body of evidence supporting the vast applicability and superiority of treatment outcomes of stem cell therapies, compared to conventional treatment options. In fact, the unmet needs within this domain have spurred the establishment of many start-ups in recent years.

To order this 500+ page report, which features 185+ figures and 220+ tables, please visit this link

Key Market Insights

Over 280 stem cell therapies are under development, most of which are allogeneic productsMore than 50% of the pipeline candidates are in the mid to late phase trials (phase II and above), and allogenic therapies (majority of which are derived from the bone marrow) make up 65% of the pipeline.

70% of pipeline candidates are based on mesenchymal stem cellsIt is worth highlighting that the abovementioned therapies are designed to treat musculoskeletal (22%), neurological (21%) and cardiovascular (15%) disorders. On the other hand, hematopoietic stem cell-based products are mostly being evaluated for the treatment of oncological disorders, primarily hematological malignancies.

Close to 85% stem cell therapy developers are based in North America and Asia-Pacific regionsWithin these regions, the US, China, South Korea and Japan, have emerged as key R&D hubs for stem cell therapies. It is worth noting that majority of the initiatives in this domain are driven by small / mid-sized companies

Over 1,500 grants were awarded for stem cell research, since 2015More than 45% of the total amount was awarded under the R01 mechanism (which supports research projects). The NCI, NHLBI, NICHD, NIDDK, NIGMS and OD emerged as key organizations that have offered financial support for time periods exceeding 25 years as well.

Outsourcing has become indispensable to R&D and manufacturing activity in this domainPresently, more than 80 industry / non-industry players, based in different regions across the globe, claim to provide contract development and manufacturing services to cater to the unmet needs of therapy developers. Examples include (in alphabetical order) Bio Elpida, Cell and Gene Therapy Catapult, Cell Tech Pharmed, GenCure, KBI Biopharma, Lonza, MEDINET, Nikon CeLL innovation, Roslin Cell Therapies, WuXi Advanced Therapies and YposKesi.

North America and Asia-Pacific markets are anticipated to capture over 80% share by 2030The stem cell therapies market is anticipated to witness an annualized growth rate of over 30% during the next decade. Interestingly, the market in China / broader Asia-Pacific region is anticipated to grow at a relatively faster rate.

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

The USD 8.5 billion (by 2030) financial opportunity within the stem cell therapies market has been analyzed across the following segments:

The report features inputs from eminent industry stakeholders, according to whom stem cell therapies are currently considered to be a promising alternatives for the treatment of a myriad of disease indications, with the potential to overcome challenges associated with conventional treatment options. The report includes detailed transcripts of discussions held with the following experts:

The research covers brief profiles of several companies (including those listed below); each profile features an overview of the company, financial information (if available), stem cell therapy portfolio and an informed future outlook.

For additional details, please visithttps://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html

or email [emailprotected]

You may also be interested in the following titles:

Contact:

Gaurav Chaudhary+1 (415) 800 3415+44 (122) 391 1091[emailprotected]

Read the original:
Stem Cell Therapy Market is estimated to be worth USD 8.5 Billion by 2030 - PRnews Leader

Read More...

Canine Stem Cell Therapy Market Size, Share Analysis by Manufacturers, Regions, Type and Application to 2026 – PRnews Leader

Thursday, November 5th, 2020

AllTheResearch, now has a research study on the Canine Stem Cell Therapy market which delivers a precise summary of the industry estimates, SWOT analysis, industry size, profit estimation and regional outlook of the business. The report offers a concise estimation of future growth prospects and obstacles awaiting market players of this industry, while further examining their existing competitive settings and business strategies.

The global Canine Stem Cell Therapy market was valued at US$ 118.5 Mn in 2018 year and is expected to reach US$ 240.7 Mn in 2026, growing at a CAGR of 9.3% during the forecast period.

Key Questions Answered in the Report:

Request for Sample with Complete TOC and Figures & Graphs @ https://www.alltheresearch.com/sample-request/206

The research report on Canine Stem Cell Therapy market, covering the COVID-19 impact, provides a comparative analysis of the historical data with the current market scenario to unveil the growth projections for the industry over the analysis period. As per the study, the Canine Stem Cell Therapy market is expected to garner substantial returns and showcase a healthy growth rate throughout the forecast duration.

The Major Players Covered in Canine Stem Cell Therapy Market Study are:

Check all key players mentioned in this report. Lets connect with the analyst @ https://www.alltheresearch.com/speak-to-analyst/206

Major Segments Covered in Canine Stem Cell Therapy Market Reports are based on types and Applications as Follows:

Based on Types Canine Stem Cell Therapy Market Segmentation:

Based on Applications Canine Stem Cell Therapy Market Segmentation:

COVID-19 Impact on Canine Stem Cell Therapy Market:

The outbreak of COVID-19 has brought along a global recession, which has impacted several industries. Along with this impact COVID Pandemic has also generated few new business opportunities for Canine Stem Cell Therapy Market. Overall competitive landscape and market dynamics of Canine Stem Cell Therapy has been disrupted due to this pandemic. All these disruptions and impacts has been analysed quantifiably in this report, which is backed by market trends, events and revenue shift analysis. COVID impact analysis also covers strategic adjustments for Tier 1, 2 and 3 players of Canine Stem Cell Therapy Market.

Get Brief Information on Pre COVID-19 Analysis and Post COVID-19 Opportunities in Canine Stem Cell Therapy Market @https://www.alltheresearch.com/impactC19-request/206

How Report will help you to make decisions for business:

About AllTheResearch:

AllTheResearch was formed with the aim of making market research a significant tool for managing breakthroughs in the industry. As a leading market research provider, the firm empowers its global clients with business-critical research solutions. The outcome of our study of numerous companies that rely on market research and consulting data for their decision-making made us realise, that its not just sheer data-points, but the right analysis that creates a difference. While some clients were unhappy with the inconsistencies and inaccuracies of data, others expressed concerns over the experience in dealing with the research-firm. Also, same-data-for-all-business roles was making research redundant. We identified these gaps and built AllTheResearch to raise the standards of research support.

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:

Contact Name: Rohan S.

Email: [emailprotected]

Phone: +1 (407) 768-2028

Visit link:
Canine Stem Cell Therapy Market Size, Share Analysis by Manufacturers, Regions, Type and Application to 2026 - PRnews Leader

Read More...

Stem Cell Banking Market to witness an impressive growth during the forecast pe – News by aeresearch

Monday, November 2nd, 2020

The latest Stem Cell Banking market research report offers a top to bottom analysis of this business sphere in terms of potential industry size, supply chain, growth dynamics, opportunity analysis, and competitive landscape. Furthermore, it extends through abstracts on various industry segments, inclusive of a rundown of the business scenario across the various regional markets. Additionally, the study provide insights into to the impact of Covid-19 pandemic and recommends strategies that could maximize ROI amid these uncertain times.

Key areas covered in the Covid-19 impact assessment:

An overview of the regional analysis:

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/341604

Other important inclusions in the Stem Cell Banking market report:

Key Questions Answered in The Report:

What will the Stem Cell Banking market growth rate?

What are the key factors driving the global Stem Cell Banking market?

Who are the key manufacturers in Stem Cell Banking market space?

What are the market opportunities and overview of the Stem Cell Banking market?

What are sales, revenue, and price analysis of top manufacturers of Stem Cell Banking market?

What are the Stem Cell Banking market opportunities and threats faced by the vendors in the global Stem Cell Banking Industry?

What are sales, revenue, and price analysis by types and applications of Stem Cell Banking Industry?

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/341604

See the original post:
Stem Cell Banking Market to witness an impressive growth during the forecast pe - News by aeresearch

Read More...

Global Tooth Regeneration Market: Industry Analysis and Forecast (2020-2027)-by Type, Application, Population Demographics and Region – re:Jerusalem

Saturday, October 10th, 2020

Global Tooth Regeneration Market was valued US$ XX Mn in 2019 and is expected to reach US$ XX Mn by 2027, at a CAGR of 6.5% during a forecast period 2020-2027.

Market Dynamics

The Research Report gives a comprehensive account of the drivers and restraints in the tooth regeneration.Somatic stem cells are composed and reprogrammed to induced pluripotent stem cells which can be placed in the dental lamina directly or placed in an absorbable biopolymer in the shape of the new tooth, which is a main source of the novel bioengineered teeth. Tooth replacement therapy is pondered to be a greatly attractive concept for the next generation bioengineered organ replacement.The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/55424

The global tooth regeneration market is mainly compelled by the high occurrence of dental problems with the new research and development activities. According to WHO, the Global Burden of Disease Study 2017 estimated that oral diseases affect close to 3.5 billion people worldwide, with caries of permanent teeth being the most common condition. Globally, it is likely that 2.3 billion people suffer from caries of permanent teeth and more than 530 million children suffer from caries of primary teeth. Additionally, positive refund policies for instance coverage of Medicaid insurance for dental loss treatment and emergence of new technologies like laser tooth generation techniques are projected to enhance the global tooth generation market throughout the estimated period.

Different researches are carried out by several academies and corporations to understand the possibility of stem cell-based regenerative medicines tooth regeneration. Though stem cell is the protuberant technology in research for tooth regeneration, several organizations are also leveraging laser, drug, and gel as mediums to regenerate teeth. For example, the Wyss Institute at Harvard University is engaged in research related to tooth regeneration using lasers. Tooth generation using stem cells is now under research through the globe. There are some key stem cells on which research are carried out such as stem cells from human exfoliated deciduous teeth (SHEDs), dental pulp stem cells, dental follicle progenitor cells (DFPCs), periodontal ligament stem cells (PDLSCs), and stem cells from apical papilla (SCAPs).A 2009 nationwide survey by the Nova South-eastern University in the U.S. publicized that around 96% of dentists expect stem cell regeneration to lead the future of the dentistry industry.However, occurrence rates are growing in low and middle-income countries. Though, some factors like the preference for endodontic treatment over tooth regeneration products in key dental surgeries and local inflammatory activity, which results in chronic complications to dental replacements, is anticipated to hamper the market throughout the forecast period.

Global Tooth Regeneration Market Segment analysis

Based on population demographics, the geriatric segment is expected to grow at a CAGR of XX% during the forecast period. According to NIH, the geriatric population has an average 18.9 remaining teeth. About 23% of the geriatric population has no teeth, making a positive market situation for manufacturing companies. The above 18 million dental procedures are anticipated to be carried out amongst the geriatric population between 2019 and 2027. Commercialization of tooth regeneration is expected to create lucrative market opportunities for industry players.Based on Type, the dentin segment accounted for a projecting share of the global tooth regeneration market in 2019, owing to the growing occurrence of dental surgery and the uprising demand for tooth regeneration in cosmetic surgery, particularly from developing economies like India, China, and Brazil.

Global Tooth Regeneration Market Regional analysis

The Asia Pacific is projected to dominate the global tooth regeneration market throughout the forecast period. Tooth regeneration addressable market is likely to be highest in the Asia Pacific, with China and India located as the major growth engines. The occurrence of tooth regeneration is projected to capture this market. Also, the number of dental procedures is anticipated to grow at the highest CAGR of ~10.8% in the Asia Pacific between 2019 and 2027. Besides, the growing incidence of dental cavities & periodontics, particularly in emerging countries like China and India has led to the rising demand for orthopedic & dental surgery.North America and Europe are estimated to collectively account for the major share of global procedures during the forecast period.

Key Developments

In June 2018, Datum Dental Ltd., the prominent provider of OSSIX brand innovative solutions for bone and tissue regeneration for dentistry, announced clearances for OSSIX Bone with Health Canada and CE Mark approval in Europe. OSSIX Bone received FDA clearance in July 2017 and was launched commercially in the USA. In April 2018, Datum Dental, the leading provider of OSSIX brand innovative solutions for bone and tissue regeneration for dentistry, announced the expansion of its global distribution network. In the USA, Dentsply Sirona Implants is now promoting the full OSSIX line.

The objective of the report is to present a comprehensive analysis of the Global Tooth Regeneration Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/55424

The report also helps in understanding Global Tooth Regeneration Market dynamics, structure by analysing the market segments and projects the Global Tooth Regeneration Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Tooth Regeneration Market make the report investors guide.Scope of the Global Tooth Regeneration Market

Global Tooth Regeneration Market, By Type

Dentin Dental Pulp Tooth EnamelGlobal Tooth Regeneration Market, By Applications

Hospitals Dental Clinics OthersGlobal Tooth Regeneration Market, By Population Demographics

Geriatric Middle-aged Adults OthersGlobal Tooth Regeneration Market, By Regions

North America Europe Asia-Pacific South America Middle East and Africa (MEA)Key Players operating the Global Tooth Regeneration Market

Unilever Straumann Dentsply Sirona 3M Zimmer Biomet Ocata Therapeutics Integra LifeSciences Datum Dental CryoLife BioMimetic Therapeutic Cook Medical

MAJOR TOC OF THE REPORT

Chapter One: Tooth Regeneration Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Tooth Regeneration Market Competition, by Players

Chapter Four: Global Tooth Regeneration Market Size by Regions

Chapter Five: North America Tooth Regeneration Revenue by Countries

Chapter Six: Europe Tooth Regeneration Revenue by Countries

Chapter Seven: Asia-Pacific Tooth Regeneration Revenue by Countries

Chapter Eight: South America Tooth Regeneration Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Tooth Regeneration by Countries

Chapter Ten: Global Tooth Regeneration Market Segment by Type

Chapter Eleven: Global Tooth Regeneration Market Segment by Application

Chapter Twelve: Global Tooth Regeneration Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Tooth Regeneration Market Report at: https://www.maximizemarketresearch.com/market-report/global-tooth-regeneration-market/55424/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

Excerpt from:
Global Tooth Regeneration Market: Industry Analysis and Forecast (2020-2027)-by Type, Application, Population Demographics and Region - re:Jerusalem

Read More...

Page 11234..10..»


2021 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick